Evidence map›Paper›PMID 39693037›Full record

ArticleEJNMMI radiopharmacy and chemistry2024

[

Alexis M Sanwick, Katherine N Haugh, Evan J Williams, Kala A Perry, Nikki A Thiele, Ivis F Chaple

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alexis M SanwickDepartment of Nuclear Engineering, University of Tennessee, Knoxville, Knoxville, TN, 37996, USA.
Katherine N HaughDepartment of Nuclear Engineering, University of Tennessee, Knoxville, Knoxville, TN, 37996, USA.
Evan J WilliamsDepartment of Nuclear Engineering, University of Tennessee, Knoxville, Knoxville, TN, 37996, USA.
Kala A PerryDepartment of Nuclear Engineering, University of Tennessee, Knoxville, Knoxville, TN, 37996, USA.
Nikki A ThieleChemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA.
Ivis F ChapleDepartment of Nuclear Engineering, University of Tennessee, Knoxville, Knoxville, TN, 37996, USA. ichaple@utk.edu.ORCID http://orcid.org/0000-0003-3951-3594

Funding

Support for Affiliated Research Teams Grant Support for Affiliated Research Teams Grant
6 · The paper itself

Abstract

backgroundNeuroendocrine tumors (NETs) are clinically diverse types of tumors that can arise anywhere in the body. Previous studies have shown that somatostatin receptors (SSTRs) are overexpressed on NET cell membranes relative to healthy tissue, allowing for tumor targeting through radiolabeled somatostatin analogs (SSAs). This work aims to develop a novel

resultsRadiochemical tracer assessment indicated that amounts as low as 0.1 nmol DFO-TOC can be effectively radiolabeled with

conclusionsIn this work, [

Indexed as

Neuroendocrine tumorsOctreotidePositron emission tomographyRadiopharmaceuticalsSomatostatin receptors

Identifiers

PMID39693037
PMCPMC11655904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.